Premium
Effects of selected adrenergic receptor agonists on human breast cancer progression, in vitro
Author(s) -
Philipose Christina,
Patel Kartik K.,
Bavadekar Supriya A.
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1038.15
Subject(s) - viability assay , phentolamine , agonist , angiogenesis , propranolol , chemistry , cell growth , cancer cell , endocrinology , receptor , metastasis , medicine , cancer research , pharmacology , in vitro , cancer , biology , biochemistry
Recent reports have suggested an association between adrenergic receptor (AR) agonists and progression of cancer leading to increased cell proliferation, angiogenesis, and metastasis. Current evidence suggests that these effects may be mediated via the β 2 ‐AR. In this study, human metastatic, hormone‐insensitive, breast cancer cells, MDA‐MB‐231, known to express β 2 ‐AR, were treated with varying concentrations (ranging from 10 −9 M to 10 −3 M) of the AR agonists, norepinephrine (NE), epinephrine (E), and isoproterenol (ISO) for 24 hr. The agonists produced a concentration‐dependent increase in cell viability in the 10 −5 to 10 −3 M range, as assessed using the XTT cell proliferation assay. Increase in cell viability observed with 10 −3 M of NE, E, and ISO was about 9–10 fold. There was no rank order of potency observed between the agonist ligands. Pretreatment with α‐ and β‐AR selective antagonists, phentolamine (10 μM), propranolol (10 μM), and ICI 118,551 (10 μM) did not inhibit the increase in cell viability. Further experiments are needed to explore the underlying mechanism of increased viability observed with these agonists, and also to assess their effects on angiogenesis and metastasis in these cells. This research work is supported by the Division of Pharmaceutical Sciences at Long Island University, Brooklyn, NY.